¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Toxicity Tests, Chronic"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® chronic active hepatitis ÇÑ±Û ¸¸¼ºÈ°µ¿°£¿°
¼³¸í   
  BÇü °£¿°À̳ª ºñAÇü£­ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼­ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Æ¯Â¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀǠħÀ±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ È²´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿­ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈ­Áõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic myelocytic leukemia
    ¸¸¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • chronic myeloproliferative disorder
    ¸¸¼º°ñ¼öÁõ½ÄÁúȯ
  • chronic obstructive pulmonary disease
    ¸¸¼ºÆó¼âÆóÁúȯ
  • chronic pain syndrome
    ¸¸¼ºÅëÁõÁõÈıº
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • chronic progressive disciform granulomatosis
    ¸¸¼ºÁøÇà¿ø¹ÝÀ°¾ÆÁ¾Áõ
  • chronic relapsing pancreatitis
    ¸¸¼ºÀç¹ßÀÌÀÚ¿°, ¸¸¼ºÀç¹ßÃéÀå¿°
  • chronic renal failure
    ¸¸¼ºÄáÆÏ±â´É»ó½Ç, ¸¸¼º½ÅºÎÀü
  • chronic vasomotor instability
    ¸¸¼ºÇ÷°ü¿îµ¿ºÒ¾ÈÁ¤
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic relapsing pancreatitis
    ¸¸¼ºÀç¹ßÀÌÀÚ¿°
  • chronic vasomotor instability
    ¸¸¼ºÇ÷°ü¿îµ¿ºÒ¾ÈÁ¤
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • digitalis toxicity
    µðÁöÅ»¸®½ºµ¶¼º.
  • free radical formation,oxygen toxicity
    ÀÚÀ¯ ·¡µðÄ® Çü¼º, »ê¼Òµ¶¼º(ß«áÈÔ¸àõ)
  • halothane, toxicity
    ÇÒ·Îź µ¶¼º
  • occupational toxicity
    Á÷¾÷¼º Áßµ¶(¼º).
  • organ toxicity
    Àå±âµ¶¼º.
  • oxygen toxicity
    »ê¼Òµ¶¼º(¡­Ô¸àõ).
  • oxygen,toxicity
    »ê¼Òµ¶¼º(ß«áÈÔ¸àõ)
  • selective toxicity
    ¼±ÅÃÀû µ¶¼º
  • selective toxicity
    ¼±ÅÃÀû µ¶¼º(àÔ÷ÉîÜÔ¸àõ)
  • subacute toxicity
    ¾Æ±Þ¼º µ¶¼º(¡­Ô¸àõ).
  • toxicity
    µ¶¼º
  • toxicity
    µ¶¼º.
  • toxicity test
    µ¶¼º½ÃÇè.
  • vinca alkaloid toxicity
    ºóÄ« ¾ËÄ®·ÎÀÌµå µ¶¼º(µ¶·Â)
  • alcoholism, chronic
    ¾ËÄÚ¿Ã Áßµ¶, ¸¸¼º(¡­ñéÔ¸)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RALT routine admission laboratory tests
SMA-6 Sequential Multiple Analysis-m-six different serum tests
I&T intolerance and toxicity
TCLP Toxicity Characteristic Leachate Procedure [EPA battery test]
tox toxicity, toxic
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TEF toxicity equivalence factor
BPT Bronchial provocation tests
CPT Conjunctival provocation tests
IVGTT I.v. glucose tolerance tests
IFT Immunofluorescence tests
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chronic atrophic laryngitis
    ¸¸¼º À§Ãà Èĵο°, ¸¸¼º À§Ã༺ Èĵο°
  • chronic bactrial prostatitis
    ¸¸¼º ¼¼±Õ¼º Àü¸³¼±¿°
  • chronic bullous dermatosis of childhood
    ¸¸¼º ¼Ò¾Æ ¼öÆ÷¼º ÇǺκ´
  • chronic carrier
    ¸¸¼º º¸±ÕÀÚ
  • chronic closed angle glaucoma
    ¸¸¼º Æó¼â°¢ ³ì³»Àå
  • chronic conjunctivitis
    ¸¸¼º °á¸·¿°
  • chronic cystic mastitis
    ¸¸¼º ³¶¼º À¯¹æ¿°
  • chronic dacryocystitis
    ¸¸¼º ´«¹° ÁÖ¸Ó´Ï ¿°Áõ, ¸¸¼º ´©³¶¿°
  • chronic dermatitis
    ¸¸¼º ÇǺο°
  • chronic diffuse sclerosing osteomyelitis
    ¸¸¼º ¹Ì¸¸¼º °æÈ­¼º °ñ¼ö¿°
    ¹Ì¸¸¼ºÀÇ Ä¡ÃßÁúȯ¿¡ ÀÇÇÑ °¨¿°¿¡¼­ ºñ·ÔµÈ´Ù. ³·Àº Á¤µµÀÇ °¨¿°¿¡ ´ëÇÑ °ñÀÇ Áõ½Ä¼º ¹ÝÀÀÀÌ´Ù. ³ë³âÃþÀÇ ¹«Ä¡¾Ç ºÎÀ§¿¡ ÁÖ·Î »ý±ä´Ù. Ưº°ÇÑ ¼Ò°ßÀº ¾ø´Ù. °ñÀÇ ¹Ì¸¸¼º °æÈ­°¡ ½ÉÇÏ°í ¾çÃø¼ºÀÌ´Ù. °æ°è´Â ºÒ¸í·áÇÏ´Ù. Á¶Á÷º´¸®ÇÐÀû ¼Ò°ßÀº Á¶¹ÐÇÏ°í ºÒ±ÔÄ¢ÇÑ °ñ¼ö, ¼¶À¯¼º °ñ¼ö°­ÀÌ´Ù.
  • chronic disease
    ¸¸¼º Áúȯ
    º´ÀÇ °æ°úÀÇ Àå´Ü¿¡ ÀÇÇÑ ºÐ·ù. º¸Åë 6°³¿ù ȤÀº l³â ÀÌ»ó °è¼ÓµÇ´Â ÁúȯÀ» ¸»Çϸç, ±Þ¼º Áúȯ°ú ´ëÀÀÇÑ´Ù. ±× Áõ¼¼°¡ ¿Ï¸¸ÇÏ°Ô ³ªÅ¸³ª Àå±â°£ Áö¼ÓÇϹǷΠ¸¸¼º Áõ»óÀ̶ó Çϸç, À̰͵µ ±Þ¼º Áúȯ¿¡¼­ÀÇ ±Þ¼º Áõ»ó¿¡ ´ëÀÀÇÏ´Â ¸»ÀÌ´Ù. ´ëÇ¥ÀûÀÎ ¸¸¼º ÁúÇÑÀ¸·Î´Â °áÇÙ, ³ªº´, ¸Åµ¶ µîÀÌ ÀÖ°í, ±Þ¼º Áúȯ¿¡¼­ ÀÌÇàÇÏ´Â °Íµµ ¸¹´Ù. ´Ü¼øÈ÷ ¾ËÄÚ¿Ã Áßµ¶À̳ª °üÀý ·ù¸ÓƼÁò µîÀÇ °æ¿ì´Â ¸¸¼ºÀ¸·Î º¸´Â °æ¿ì°¡ ¸¹´Ù.
  • chronic empyema
    ¸¸¼º ³óÈä
  • chronic endemic dental fluorosis
    ¸¸¼º À¯Ç༺ Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ, ¸¸¼º dzÅ伺 Ä¡¾Æ ºÒ¼Ò Ä§ÂøÁõ
  • chronic erythematous atrophic candidosis
    ¸¸¼º È«¹Ý¼º À§Ã༺ ĵµð´ÙÁõ
  • chronic exposure
    ¸¸¼º ³ëÃâ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
breath tests Any tests done on exhaled air.
(12 Dec 1998)
bronchial provocation tests Tests involving inhalation of allergens (nebulised or in dust form), nebulised pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma.
(12 Dec 1998)
caloric tests Elicitation of a rotatory nystagmus by stimulating the saemicircular canals with water or air which is above or below body temperature. In warm caloric stimulation a rotatory nystagmus is developed toward the side of the stimulated ear; in cold, away from the stimulated side. Absence of nystagmus indicates the labyrinth is not functioning.
(12 Dec 1998)
carcinogenicity tests Tests to experimentally measure the tumour-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumours or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumour developed. Though this test differs from the DNA-repair and bacterial microsome mutagenicity tests, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
(12 Dec 1998)
pancreatic function tests Tests based on the biochemistry and physiology of the exocrine pancreas and involving analysis of blood, duodenal contents, feces, or urine for products of pancreatic secretion.
(12 Dec 1998)
gel diffusion precipitin tests Precipitin test's in which the immune precipitate forms in a gel medium (usually agar) into which one or both reactants have diffused; generally classified in two types, in one dimension, and in two dimensions.
Synonym: gel diffusion reactions.
(05 Mar 2000)
gel diffusion precipitin tests in one dimension Precipitin test's in which antigen solution and antibody incorporated in agar are layered in tubes, permitting effective diffusion in the vertical dimension; the antibody-containing agar may be overlaid directly with antigen solution (single (gel) diffusion in one dimension).
(05 Mar 2000)
gel diffusion precipitin tests in two dimensions Precipitin test's made in a layer of agar that permits radial diffusion, in both of the horizontal dimensions, of one or both reactants. Double (gel) diffusion in two dimensions (Ouchterlony test, technique, or method) incorporates antigen and antibody solutions placed in separate wells in a sheet of plain agar, permitting radial diffusion of both reactants; this method is widely used to determine antigenic relationships; the bands of precipitate that form where the reactants meet in optimal concentration are of three patterns, referred to as reaction of identity, reaction of partial identity (cross-reaction), and reaction of nonidentity.
(05 Mar 2000)
patch tests Skin tests in which the sensitiser is applied to a patch of cotton cloth or gauze held in place for approximately 48-72 hours. It is used for the elicitation of a contact hypersensitivity reaction.
(12 Dec 1998)
respiratory function tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc.
(12 Dec 1998)
personality tests Standardised objective tests designed to facilitate the evaluation of personality.
(12 Dec 1998)
microbial sensitivity tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
(12 Dec 1998)
micronucleus tests Induction and quantitative measurement of chromosomal damage leading to the formation of micronuclei in cells which have been exposed to genotoxic agents or ionizing radiation.
(12 Dec 1998)
clinical chemistry tests Laboratory tests demonstrating the presence of physiologically significant substances in the blood, urine, tissue, and body fluids with application to the diagnosis or therapy of disease.
(12 Dec 1998)
placental function tests Methods used for the assessment of placental function.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á